January 08, 2014 9:36am EST
Download as PDF
Latin American Presence Continues to Grow
Product Offering Expands With Registration of New Prescription and
Nutritional Products
Platform for Near-Term Launch of 4Kscore ™ Prostate Cancer
Test
Enhances Commercial Synergies Among OPKO Units
MIAMI--(BUSINESS WIRE)--
OPKO Health, Inc. (NYSE: OPK )
has completed the acquisition of Laboratorio Arama de Uruguay Limitada
("Arama"). Domiciled in Montevideo, Uruguay, Arama adds to our growing
Latin American presence in the important Mercosur economic region and
complements our business activities in Chile, Mexico and Brazil.
OPKO will broaden Arama’s product portfolio by registering new
prescription and nutritional products for the Uruguayan market. These
products are currently being commercialized by other OPKO units.
"We are delighted to welcome Arama to the growing OPKO family and to
broaden the global commercial prospects for our product pipeline," said
Phillip Frost, M.D., Chairman and CEO of OPKO. "This acquisition
establishes a footprint in Uruguay and should facilitate our commercial
expansion into neighboring Argentina. We also expect Arama to market our 4Kscore ™
product, OPKO’s new test to more accurately detect and grade prostate
cancer and allow patients to avoid many unnecessary prostate biopsies."
About OPKO Health, Inc.
OPKO is a multinational biopharmaceutical and diagnostics company that
seeks to establish industry leading positions in large, rapidly growing
markets by leveraging its discovery, development and commercialization
expertise and novel and proprietary technologies.
This press release contains "forward-looking statements," as that
term is defined under the Private Securities Litigation Reform Act of
1995 (PSLRA), which statements may be identified by words such as
"expects," "plans," "projects," "will," "may," "anticipates,"
"believes," "should," "intends," "estimates," and other words of similar
meaning, including statements regarding the benefits and synergies
resulting from the acquisition of Arama, including whether Arama will
provide a platform to commercialize existing and future OPKO products
and enhance synergies among our various units, whether OPKO will be able
to broaden its commercial prospects and global reach and expand into
Argentina, whether OPKO will broaden Arama’s product portfolio by
registering new prescription and nutritional products for the Uruguayan
market, whether OPKO's portfolio of products in Latin America will grow,
whether Arama will provide a commercial platform that supports the
near-term launch of OPKO's 4Kscore™, the timing for the launch of the
4Kscore™, the potential benefits of the 4Kscore™ and its ability to more
accurately detect and grade prostate cancer, whether OPKO or Arama will
be able to successfully commercialize the 4Kscore™, as well as other
non-historical statements about our expectations, beliefs or intentions
regarding our business, technologies and products, financial condition,
strategies or prospects. Many factors could cause our actual activities
or results to differ materially from the activities and results
anticipated in forward-looking statements. These factors include those
described in our filings with the Securities and Exchange Commission, as
well as risks inherent in funding, developing and obtaining regulatory
approvals of new, commercially-viable and competitive products and
treatments. In addition, forward-looking statements may also be
adversely affected by general market factors, competitive product
development, product availability, federal and state regulations and
legislation, the regulatory process for new products and indications,
manufacturing issues that may arise, patent positions and litigation,
among other factors. The forward-looking statements contained in this
press release speak only as of the date the statements were made, and we
do not undertake any obligation to update forward-looking statements. We
intend that all forward-looking statements be subject to the safe-harbor
provisions of the PSLRA.
OPKO Health, Inc.
Steven D. Rubin or Juan F. Rodriguez, 305-575-4100
Source: OPKO Health, Inc.
Released January 8, 2014
email Email Alerts
location_city Company Profile
contact_page Contacts
rss_feed RSS News Feed
account_tree Sitemap
Apply on OPKO Health (Ireland)’s careers page